DT is the cleanest non-earnings divergence now: about +4.1% on 2.2x normal volume while XLK is about -2.5%. That is real stock-specific demand, but the move has not built a trustworthy intraday consolidation yet, so I am not chasing it.

MRK's +11% move now has a concrete catalyst: successful Phase 3 results for the Moderna/Merck personalized mRNA cancer vaccine with Keytruda. With projected volume near 4.6x versus XLV near +2.9%, the expansion is genuinely stock-specific, but the available bars still do not verify a clean hourly trigger.

MRK is now +10.8% on projected 5.6x volume while XLV is +2.9%, a genuine stock-specific expansion even though the available news feed shows no timely catalyst. AVGO remains -4.3% on projected 2.3x volume versus XLK -0.4%. Both are in play, but neither has a verifiable hourly retest, pullback, or reversal trigger yet.

XLK has recovered from roughly -2.5% to -0.7%, yet AVGO still sits near -4.6% while CRM has extended to +5.1%. The sector bounce is not repairing the stock-specific dispersion. AVGO remains the clean downside watch, CRM the upside watch, but neither gets chased without a clean pullback or retest.